Climb Bio

Climb Bio DSCR

The Debt Service Coverage Ratio (DSCR) of Climb Bio (CLYM) as of Oct 17, 2026 is -212.33.

DSCR

-212.33

Last updated:

Debt Service Coverage Ratio (DSCR) of Climb Bio is 2025 -212.33 . Debt Service Coverage Ratio (DSCR) of Climb Bio was 2024 - . It decreases by % lower compared to the previous year.

The Climb Bio DSCR history

The Climb Bio DSCR history
YEARDSCRYoY
-212.33—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Climb Bio Stock analysis

What does Climb Bio do? Climb Bio Inc, headquartered in Wilmington, Delaware, is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders. The company, which went public on August 10, 2021, employs 30 full-time staff and is advancing a pipeline of product candidates targeting validated mechanisms for conditions including epilepsy, chronic pain, and psychiatric disorders. Its lead program, ETX-123, aims to improve safety and tolerability of Kv7.2/3 potassium channel openers. Climb Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Climb Bio stock

Debt Service Coverage Ratio (DSCR) of Climb Bio is -212.33 in 2025.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) Climb Bio since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s Climb Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Climb Bio

All Key Metrics — Climb Bio